{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T16:16:25Z","timestamp":1782922585231,"version":"3.54.5"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004896","name":"Eisai Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004896","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.eplepsyres.2024.107339","type":"journal-article","created":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T16:26:19Z","timestamp":1709396779000},"page":"107339","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Perampanel for the treatment of epilepsy with genetic aetiology: Real-world evidence from the PERMIT Extension study"],"prefix":"10.1016","volume":"202","author":[{"given":"Norman","family":"Delanty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv","family":"Mohanraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Shankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Wehner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda J.","family":"Stephen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendyl","family":"D\u2019Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheri","family":"Cappucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"McMurray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Sainz-Fuertes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Villanueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2024.107339_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.630366","article-title":"Perampanel improves cortical myoclonus and disability in progressive myoclonic epilepsies: a case series and a systematic review of the literature","volume":"12","author":"Assenza","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.eplepsyres.2024.107339_bib2","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s10072-022-06452-7","article-title":"Efficacy and tolerability of perampanel in a patient with Late-Onset myoclonic epilepsy in Down syndrome (LOMEDS): a case report","volume":"44","author":"Corniello","year":"2023","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.eplepsyres.2024.107339_bib3","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.seizure.2019.12.012","article-title":"Open-label, uncontrolled retrospective study of perampanel in adults with Lennox-Gastaut syndrome","volume":"75","author":"Crespel","year":"2020","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2024.107339_bib4","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3389\/fgene.2018.00020","article-title":"Next generation sequencing methods for diagnosis of epilepsy syndromes","volume":"9","author":"Dunn","year":"2018","journal-title":"Front. Genet."},{"key":"10.1016\/j.eplepsyres.2024.107339_bib5","unstructured":"Eisai Inc., Fycompa\u00ae (perampanel) Prescribing Information, 2021. Available at: \u3008https:\/\/www.fycompa.com\/media\/media\/Files\/Fycompa\/Fycompa_Prescribing_Information.pdf\u3009."},{"key":"10.1016\/j.eplepsyres.2024.107339_bib6","unstructured":"European Medicines Agency., Fycompa\u00ae (perampanel) Summary of Product Characteristics, 2023. Available at: \u3008https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/fycompa-epar-product-information_en.pdf\u3009."},{"key":"10.1016\/j.eplepsyres.2024.107339_bib7","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1212\/WNL.0b013e3182635735","article-title":"Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304","volume":"79","author":"French","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2024.107339_bib8","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1528-1167.2012.03638.x","article-title":"Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305","volume":"54","author":"French","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2024.107339_bib9","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1212\/WNL.0000000000001930","article-title":"Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy A randomized trial","volume":"85","author":"French","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2024.107339_bib10","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1111\/epi.17235","article-title":"Big data analysis of ASM retention rates and expert ASM algorithm: a comparative study","volume":"63","author":"H\u00e5kansson","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2024.107339_bib11","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1517\/17460441.2014.891580","article-title":"The discovery and development of perampanel for the treatment of epilepsy","volume":"9","author":"Hanada","year":"2014","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.eplepsyres.2024.107339_bib12","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/epi4.12360","article-title":"Genomic and clinical predictors of lacosamide response in refractory epilepsies","volume":"4","author":"Heavin","year":"2019","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.eplepsyres.2024.107339_bib13","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1111\/epi.17236","article-title":"ILAE definition of the idiopathic generalized epilepsy syndromes: position statement by the ILAE task force on nosology and definitions","volume":"63","author":"Hirsch","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2024.107339_bib14","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1038\/s41588-023-01485-w","article-title":"GWAS meta-analysis of over 29,000 people with epilepsy identifies 26 risk loci and subtype-specific genetic architecture","volume":"55","author":"ILAE","year":"2023","journal-title":"Nat. Genet."},{"issue":"Suppl 9","key":"10.1016\/j.eplepsyres.2024.107339_bib15","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1528-1167.2005.00309.x","article-title":"Epidemiology of idiopathic generalized epilepsies","volume":"46","author":"Jallon","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2024.107339_bib16","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.braindev.2020.02.007","article-title":"Perampanel for nonepileptic myoclonus in Angelman syndrome","volume":"42","author":"Kawano","year":"2020","journal-title":"Brain Dev."},{"key":"10.1016\/j.eplepsyres.2024.107339_bib17","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1212\/WNL.0b013e318254473a","article-title":"Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures","volume":"78","author":"Krauss","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2024.107339_bib18","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1111\/epi.17601","article-title":"Long-term effectiveness of add-on perampanel in patients with Lennox-Gastaut syndrome: a multicenter retrospective study","volume":"64","author":"Matricardi","year":"2023","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2024.107339_bib19","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1002\/acn3.51828","article-title":"Efficacy of perampanel in pediatric epilepsy with known and presumed genetic etiology","volume":"10","author":"Miao","year":"2023","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.eplepsyres.2024.107339_bib20","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.neurol.2020.03.018","article-title":"Genetic\/idiopathic generalized epilepsies: not so good as that!","volume":"176","author":"Nilo","year":"2020","journal-title":"Rev. Neurol. (Paris)"},{"key":"10.1016\/j.eplepsyres.2024.107339_bib21","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/epi.17530","article-title":"Perampanel as precision therapy in rare genetic epilepsies","volume":"64","author":"Nissenkorn","year":"2023","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2024.107339_bib22","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1159\/000508357","article-title":"The effectiveness of perampanel for myoclonic seizures in Down syndrome with isodicentric chromosome 21","volume":"12","author":"Obara","year":"2020","journal-title":"Case Rep. Neurol."},{"key":"10.1016\/j.eplepsyres.2024.107339_bib23","doi-asserted-by":"crossref","first-page":"356","DOI":"10.5698\/1535-7597.18.6.356","article-title":"Genetics of focal epilepsies: what do we know and where are we heading?","volume":"18","author":"Perucca","year":"2018","journal-title":"Epilepsy Curr."},{"key":"10.1016\/j.eplepsyres.2024.107339_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1182304","article-title":"The broad-spectrum activity of perampanel: state of the art and future perspective of AMPA antagonism beyond epilepsy","volume":"14","author":"Perversi","year":"2023","journal-title":"Front. Neurol."},{"issue":"Suppl 1","key":"10.1016\/j.eplepsyres.2024.107339_bib25","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/epi.14456","article-title":"Perampanel: does it have broad-spectrum potential?","volume":"60","author":"Potschka","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2024.107339_bib26","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1684\/epd.2022.1443","article-title":"Use of perampanel in children with refractory epilepsy of genetic aetiology","volume":"24","author":"Qu","year":"2022","journal-title":"Epileptic Disord."},{"issue":"Suppl 181","key":"10.1016\/j.eplepsyres.2024.107339_bib27","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1600-0404.2005.00505.x","article-title":"New antiepileptic drugs in practice--how do they perform in the real world?","author":"Sander","year":"2005","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.eplepsyres.2024.107339_bib28","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: position paper of the ILAE commission for classification and terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2024.107339_bib29","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.yebeh.2016.10.025","article-title":"Randomized controlled antiepileptic drug trials miss almost all patients with ongoing seizures","volume":"66","author":"Steinhoff","year":"2017","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2024.107339_bib30","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s13311-020-00835-4","article-title":"From genetic testing to precision medicine in epilepsy","volume":"17","author":"Striano","year":"2020","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.eplepsyres.2024.107339_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21207784","article-title":"Genetic landscape of common epilepsies: advancing towards precision in treatment","volume":"21","author":"Thakran","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.eplepsyres.2024.107339_bib32","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1111\/j.1528-1167.2008.01618_2.x","article-title":"Clinical relevance of patients with epilepsy included in clinical trials","volume":"49","author":"Tlusta","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2024.107339_bib33","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1684\/epd.2016.0842","article-title":"Lafora disease","volume":"18","author":"Turnbull","year":"2016","journal-title":"Epileptic Disord."},{"key":"10.1016\/j.eplepsyres.2024.107339_bib34","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1007\/s00415-021-10751-y","article-title":"PERMIT study: a global pooled analysis study of the effectiveness and tolerability of perampanel in routine clinical practice","volume":"269","author":"Villanueva","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.eplepsyres.2024.107339_bib35","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/epi4.12575","article-title":"PROVE: retrospective, non-interventional, Phase IV study of perampanel in real-world clinical care of patients with epilepsy","volume":"7","author":"Wechsler","year":"2022","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.eplepsyres.2024.107339_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2023.109369","article-title":"Effectiveness, safety and tolerability of perampanel by age group when used to treat people with focal and generalized epilepsy in clinical practice: the PERMIT Extension study","volume":"147","author":"Wheless","year":"2023","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2024.107339_bib37","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1007\/s00415-021-10834-w","article-title":"GABRB3-related epilepsy: novel variants, clinical features and therapeutic implications","volume":"269","author":"Yang","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.eplepsyres.2024.107339_bib38","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.eplepsyres.2019.02.014","article-title":"Efficacy and tolerability of perampanel in pediatric patients with Dravet syndrome","volume":"154","author":"Yoshitomi","year":"2019","journal-title":"Epilepsy Res."}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121124000548?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121124000548?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T23:31:18Z","timestamp":1737847878000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121124000548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":38,"alternative-id":["S0920121124000548"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2024.107339","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Perampanel for the treatment of epilepsy with genetic aetiology: Real-world evidence from the PERMIT Extension study","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2024.107339","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107339"}}